Patent: 9,987,326
✉ Email this page to a colleague
Summary for Patent: 9,987,326
Title: | Klotho protein and related compounds for the treatment and diagnosis of cancer |
Abstract: | Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents. |
Inventor(s): | Koeffler; H. Phillip (Los Angeles, CA), Wolf; Ido (Or Yehuda, IL), Rubinek; Tamar (Or Yehuda, IL), Kaufman; Bella (Kiryat Ono, IL), Abramovitch; Lilach (Kfar Saba, IL) |
Assignee: | Tel HaShomer Medical Research Infrastructure and Services Ltd. (Ramat Gan, IL) CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) |
Application Number: | 13/419,610 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,987,326 |
Patent Claims: | see list of patent claims |
Details for Patent 9,987,326
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2039-02-26 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2039-02-26 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |